COMMUNIQUÉS West-GlobeNewswire

Avivagen Announces Approval from TSX Venture Exchange for Extension of Warrants

12/03/2018 - 11:30

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. OTTAWA, March 12, 2018 (GLOBE NEWSWIRE) -- [...]

Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis

12/03/2018 - 11:05

-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. ( [...]

PotNetwork Holding Unveils New Products At World’s Premiere Trade Show, ASD Market Week

12/03/2018 - 11:00

FT. LAUDERDALE, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holding, Inc. (OTC Pink:POTN) (“Company”), announced today that its wholly owned subsidiary, Diamond CBD, Inc., is currently [...]

Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome

12/03/2018 - 11:00

LOS ANGELES, March 12, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR ) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the gut microbiome to treat [...]

Quit smoking, nicotine free: Oriola to distribute Acetium® lozenge in Finland

12/03/2018 - 09:30

Biohit Oyj, Press release, March 12, 2018 at 10:30 am local time (EET) Biohit Oyj and Oriola Oy have signed an agreement for the distribution of the smoking cessation product, Acetium lozenge in Pharmacies and other [...]

Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting

12/03/2018 - 08:01

Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting - Clinical and real-world insights on recombinant human parathyroid hormone ( 1-84) (rhPTH[1-84]) and [...]

Bavarian Nordic Awards Restricted Stock Units to Executive Management

12/03/2018 - 07:56

COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board of Directors of [...]

Bavarian Nordic Announces Annual Report 2017

12/03/2018 - 07:43

COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2017. Below is a summary of business progress, financial performance for the year and financial [...]

Novartis announces changes to the Executive Committee to support strategic priorities

12/03/2018 - 07:01

Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger named Chief Ethics, Risk and [...]

Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques

12/03/2018 - 07:01

Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN Shannon Klinger est [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

12/03/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 12 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

IBA SA : IBA signs three new Proteus®ONE contracts with Proton Partners International

12/03/2018 - 07:01

IBA signs three new Proteus ® ONE contracts with Proton Partners International IBA to install three additional Proteus ® ONE compact proton therapy solutions in the UK Louvain-La-Neuve, Belgium, 12 March 2018 - IBA (Ion [...]

IBA SA : IBA signe trois nouveaux contrats Proteus®ONE avec Proton Partners International

12/03/2018 - 07:01

IBA signe trois nouveaux contrats Proteus ® ONE avec Proton Partners International IBA va installer trois solutions compactes de protonthérapie Proteus ® ONE supplémentaires au Royaume-Uni Louvain-la-Neuve, Belgique, 12 [...]

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

12/03/2018 - 01:00

Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors SAN DIEGO, March 11, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (Arcturus or the Company) (NASDAQ: ARCT ), an RNA [...]

Immutep Raises A$6.85m Through Institutional Placement

12/03/2018 - 00:55

A$6.85m raised through share institutional placement to drive immuno-oncology development programs Placement of new ordinary shares to leading Australian healthcare institutional investors Platinum Asset Management and [...]

Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With MSD

12/03/2018 - 00:25

SYDNEY, Australia, March 11, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement [...]

Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System

10/03/2018 - 18:16

Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO - March 10, 2018 - Medtronic plc (NYSE: MDT) today [...]

Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

10/03/2018 - 15:03

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron announce plans to make Praluent ® more accessible and affordable for patients with the greatest health risk and unmet need Precision medicine [...]

Sanofi et Regeneron annoncent leurs plans pour rendre Praluent® plus facilement accessible et économiquement abordable aux patients à risque élevé présentant d'importants besoins non satisfaits

10/03/2018 - 15:03

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et Regeneron annoncent leurs plans pour rendre Praluent ® plus facilement accessible et économiquement abordable aux patients à risque élevé [...]